Biopharm Co. Seelos Files For Ch. 11 After Nasdaq Delisting
By Hilary Russ · November 18, 2024, 5:38 PM EST
Publicly traded biopharmaceutical company Seelos Therapeutics Inc. sought Chapter 11 protection in New York on Saturday, citing between $10 million and $50 million in estimated liabilities....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login